Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TetMYB + Tislelizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TetMYB | MYB vaccine | TetMYB is a DNA vaccine comprised of a modified full-length MYB coding region linked to tetanus peptides, which results in enhanced immune response to MYB expressing tumor cells (Gastroenterology, Volume 154, Issue 6, Supplement 1, May 2018, Pages S-1269, PMID: 25671128, PMID: 31650066). | ||
Tislelizumab | BGB-A317 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 | Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03287427 | Phase I | TetMYB + Tislelizumab | MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial (MYPHISMO) | Completed | AUS | 0 |